RPL17 and neoplasm: While the role of TMB as a predictive marker of immunotherapy response in patients with HCC remains to be elucidated, in a large-scale study [56] conducted on 27 tumor types, TMB was correlated with ORR to anti-PD1 therapy, with a median TMB of 4–5 mutations/Mb in the 43 patients with HCC (21 treated with nivolumab and 22 treated with durvalumab).